CSF total tau, aβ42 and phosphorylated tau protein as biomarkers for Alzheimer's disease
CSF total tau, aβ42 and phosphorylated tau protein as biomarkers for Alzheimer's disease
复制标题
脑脊液总 tau、aβ42 和磷酸化 tau 蛋白作为阿尔茨海默病的生物标志物
DOI：
10.1385/mn:24:1-3:087
复制
发表时间：
2001-08-01
影响因子：
5.1
通讯作者：
Hampel, H
中科院分区：
文献类型：
--
作者：
Blennow, K;Vanmechelen, E;Hampel, H
随着有效对症治疗的到来和可能延缓进展的药物的承诺，我们现在需要在疾病的早期阶段识别阿尔茨海默病（AD）。为了更早更准确地诊断AD，人们的注意力已经转向外周生化标志物。本文综述了有前途的潜在的脑脊液（CSF）生物标志物的AD集中在其在临床诊断中的作用。特别是，两个生化标志物，CSF总tau（t-tau）蛋白和42个氨基酸形式的β-淀粉样蛋白（A β 42），表现令人满意，足以实现在痴呆患者的临床诊断环境中的作用，以及来自基本临床检查，遗传筛查和脑成像的累积信息。这些CSF标记物对于区分早期或初期AD与年龄相关的记忆障碍、抑郁症和一些继发性痴呆特别有用。然而，为了区分AD与其他原发性痴呆症，需要更准确和特异性的标记物。初步证据有力地表明，在CSF中特定位点磷酸化的tau蛋白的定量可改善AD的早期检测、鉴别诊断和疾病进展的跟踪。
With the arrival of effective symptomatic treatments and the promise of drugs that may delay progression, we now need to identify Alzheimer's disease (AD) at an early stage of the disease. To diagnose AD earlier and more accurately, attention has been directed toward peripheral biochemical markers. This article reviews promising potential cerebrospinal fluid (CSF) biomarkers for AD focussing on their role in clinical diagnosis. In particular, two biochemical markers, CSF total tau (t-tau) protein and the 42 amino acid form of beta-amyloid (Abeta42), perform satisfactorily enough to achieve a role in the clinical diagnostic settings of patients with dementia together with the cumulative information from basic clinical work-up, genetic screening, and brain imaging. These CSF markers are particularly useful to discriminate early or incipient AD from age-associated memory impairment, depression, and some secondary dementias. In order to discriminate AD from other primary dementia disorders, however, more accurate and specific markers are needed. Preliminary evidence strongly suggests that quantification of tau phosphorylated at specific sites in CSF improves early detection, differential diagnosis, and tracking of disease progression in AD.